A Retrospective Study of Lenvatinib Monotherapy or Combined With Programmed Cell Death Protein 1 Antibody in the Treatment of Patients With Hepatocellular Carcinoma or Intrahepatic Cholangiocarcinoma in China

Lenvatinib has been ratified as a first-line medication for advanced liver tumors by the American Food and Drug Administration. To assess the effectiveness and security of Lenvatinib in the Chinese population in a real-world setting, we enrolled 48 patients with unresectable liver cancer, managed fr...

Descripción completa

Detalles Bibliográficos
Autores principales: Zhu, Sihui, Liu, Chenxi, Dong, Yanbing, Shao, Jie, Liu, Baorui, Shen, Jie
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Frontiers Media S.A. 2021
Materias:
Oncology
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8718677/
https://www.ncbi.nlm.nih.gov/pubmed/34976828
http://dx.doi.org/10.3389/fonc.2021.788635

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8718677/
https://www.ncbi.nlm.nih.gov/pubmed/34976828
http://dx.doi.org/10.3389/fonc.2021.788635

Ejemplares similares